Loading
TAR-210 is an experimental small molecule (intravesical drug-releasing system) from Janssen Research & Development in phase 3 trials for bladder & urothelial cancer, aimed at FGFR2.
TAR-210 (JNJ-42756493) is a small molecule (intravesical drug-releasing system) developed by Janssen Research & Development. Its target is FGFR2 (the sponsor names FGFR (fibroblast growth factor receptor)). The sponsor states: An intravesical system that provides approximately two years of continuous local bladder delivery of erdafitinib, an FGFR inhibitor, for patients with high-risk non-muscle-invasive bladder cancer harbouring susceptible FGFR alterations. ClinicalTrials.gov describes the intervention as: TAR-210 will be administered intravesically. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06919965 (A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer), in bladder & urothelial cancer. The largest, NCT06919965, plans to enrol 220 participants with primary completion expected 2028-04-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
TAR-210 is an intravesical system that releases erdafitinib over months; the device is not shown.
An intravesical system that provides approximately two years of continuous local bladder delivery of erdafitinib, an FGFR inhibitor, for patients with high-risk non-muscle-invasive bladder cancer harbouring susceptible FGFR alterations. Connects to FGFR2.
1.TAR-210 slips into a pocket on FGFR2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TAR-210" OR ABSTRACT:"TAR-210" OR TITLE:"JNJ-42756493" OR ABSTRACT:"JNJ-42756493") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TAR-210, not a curated reading list.
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
Shares FGFR2, Bladder & urothelial cancer and the tag pipeline.
Shares FGFR2 and the tag pipeline.
Shares FGFR2, Bladder & urothelial cancer and the tag pipeline.
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
Shares Johnson & Johnson and the tag pipeline.